Meningitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Meningitis - Pipeline Review, H1 2016

Meningitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Meningitis - Pipeline Review, H1 2016
Published Jun 15, 2016
63 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Meningitis - Pipeline Review, H1 2016, provides an overview of the Meningitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meningitis
- The report reviews pipeline therapeutics for Meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Meningitis therapeutics and enlists all their major and minor projects
- The report assesses Meningitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Meningitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Meningitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meningitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8202IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Meningitis Overview81
Therapeutics Development92
  Pipeline Products for Meningitis Overview91
  Pipeline Products for Meningitis Comparative Analysis101
Meningitis Therapeutics under Development by Companies111
Meningitis Therapeutics under Investigation by Universities/Institutes121
Meningitis Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Meningitis Products under Development by Companies161
Meningitis Products under Investigation by Universities/Institutes171
Meningitis Companies Involved in Therapeutics Development189
  Adenium Biotech ApS181
  Amplyx Pharmaceuticals, Inc.191
  Chiesi Farmaceutici SpA201
  ContraFect Corporation211
  Genticel S.A.221
  LG Life Science LTD.231
  Matinas BioPharma Holdings, Inc.241
  Sanofi Pasteur SA251
  Viamet Pharmaceuticals, Inc.261
Meningitis Therapeutics Assessment279
  Assessment by Monotherapy Products271
  Assessment by Target282
  Assessment by Mechanism of Action302
  Assessment by Route of Administration322
  Assessment by Molecule Type342
Drug Profiles3618
  amphotericin B Drug Profile362
  AP-114 Drug Profile381
  CF-302 Drug Profile391
  CF-303 Drug Profile401
  CF-305 Drug Profile411
  CF-309 Drug Profile421
  Eupenta Drug Profile431
  LBVD Drug Profile441
  meningitis vaccine Drug Profile451
  meropenem Drug Profile461
  pneumococcal [serotype 4, 6A] vaccine Drug Profile471
  Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis Drug Profile481
  Streptococcus pneumonia vaccine Drug Profile491
  tuberculous meningitis vaccine Drug Profile501
  viral vaccine Drug Profile511
  VT-1129 Drug Profile522
Meningitis Dormant Projects541
Meningitis Discontinued Products551
Meningitis Product Development Milestones566
  Featured News &Press Releases561
    Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis561
    Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis561
    Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015571
    Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta571
    Sep 11, 2014: Viamet Receives Orphan Drug Designation for VT-1129581
    Oct 25, 2010: Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants581
    Jun 08, 2010: Novartis receives Health Canada approval of Menveo to prevent meningococcal disease581
    Mar 18, 2010: Novartis receives approval in the European Union for Menveo, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease591
    Feb 22, 2010: Novartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease591
    Jun 30, 2009: Novartis receives Complete Response letter from the US Food and Drug Administration for its investigational vaccine Menveo601
    May 06, 2008: Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial601
    Jan 09, 2008: New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants601
    Nov 15, 2007: New data for Menveo vaccine show excellent immune response and broad protection for infants against meningococcal meningitis611
Appendix622
  Methodology621
  Coverage621
  Secondary Research621
  Primary Research621
  Expert Panel Validation621
  Contact Us621
  Disclaimer631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Meningitis - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Meningitis-Pipeline-Review-H1-2016-2088-15956>
  
APA:
Global Markets Direct - Market Research. (2016). Meningitis - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Meningitis-Pipeline-Review-H1-2016-2088-15956>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.